Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
2022 events¹ (expected)
NME Lead
Regulatory
H1
177 Lu-PSMA-617 mCRPC (US/EU)
Other readouts
H1
sabatolimab HR-MDS Ph2
decisions
H1
alpelisib PROS (US)
H1
CosentyxⓇ Lichen planus Ph2 PRELUDE
H2
ScemblixⓇ 3L CML (JP/EU)
H1
Cosentyx® AS IV Ph3 INVIGORATE-1
H2
tislelizumab ESCC 2L (US)
H1
icenticaftor COPD Ph2b
Submissions
H1
H1/H2
H2
H2
H1/H2 JakaviⓇ acute & chronic GVHD (EU/JP)
H1/H2 KymriahⓇ r/r follicular lymphoma (US/EU/JP)
H1/H2 BeovuⓇ DME (US/EU/JP)
ensovibep COVID-19 (US)
H1/H2 Cosentyx® HS (EU/US)
tislelizumab NSCLC (EU/US)
tislelizumab 1L Nasopharyngeal cancer (US)
Cosentyx® Psoriatic Arthritis IV (US)
H2
UNR844 presbyopia Ph2 READER
Ph3/pivotal study
H1
CosentyxⓇ peripheral SpA
starts
H1
OAV101 SMA IT STEER
H1
ensovibep COVID-19 (EMPATHY Part B)
H2
JDQ443 NSCLC mono
H2
ianalumab Sjögren's Syndrome
H2
ianalumab Lupus Nephritis
H2
ociperlimab solid tumors
Submissions- H2
canakinumab NSCLC Ph3 Canopy A
H2
177 Lu-PSMA-617 nmCRPC
enabling
H2
iptacopan PNH Ph3 APPLY-PNH
H2
YTB323 2L DLBCL
readouts
H2
KisqaliⓇ HR+/HER2- BC (adj)2 Ph3 NATALEE
H2
OAV101 SMA IT Ph3b STRENGTH
H2
177 Lu-PSMA-617 MCRPC1, pre-taxane Ph3 PSMAfore
1. Selected.
2. Event driven, could move to early 2023.
19 Investor Relations | Q4 2021 Results
3
INNOVATION
1 NOVARTIS | Reimagining MedicineView entire presentation